CoChat

Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index; 17 of the 24 sources its claims cite were checked for support.

Abstract

Abstract Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Design Active comparator, new user cohort study. Setting Primary care practices contributing data to the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics Admitted Patient Care and Office for National Statistics Death Registration databases. Participants Patients with type 2 diabetes. Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020. Both cohorts were followed until 29 March 2021. Main outcome measures The primary outcome was suicidality, defined as a composite of suicidal ideation, self-harm, and suicide. Secondary outcomes were each of these events considered separately. Propensity score fine stratification weighted Cox proportional hazards models were fitted to estimate hazard ratios and 95% confidence intervals (CIs) to estimate the average treatment effect among the treated patients. Results The first cohort included 36 082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234 028 DPP-4 inhibitor users (median follow-up 1.7 years). In crude analyses, GLP-1 receptor agonist use was associated with an increased incidence of suicidality compared with DPP-4 inhibitors (crude incidence rates 3.9 v 1.8 per 1000 person years, respectively; hazard ratio 2.08, 95% CI 1.83 to 2.36). This estimate decreased to a null value after confounding factors were accounted for (hazard ratio 1.02, 95% CI 0.85 to 1.23). The second cohort included 32 336 GLP-1 receptor agonist users (median follow-up 1.2 years) and 96 212 SGLT-2 inhibitor users (median follow-up 1.2 years). Similarly, GLP-1 receptor agonist use was associated with an increased risk of suicidality compared with SGLT-2 inhibitors in crude analyses (crude incidence rates 4.3 v 2.7 per 1000 person years; hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12). Similar findings were observed when suicidal ideation, self-harm, and suicide were analysed separately in both cohorts. Conclusions In this large cohort study, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with the use of DPP-4 inhibitors or SGLT-2 inhibitors in patients with type 2 diabetes.

Overview

CoChat Summary

## TL;DR

In this active-comparator, new-user cohort study of patients with type 2 diabetes, GLP-1 receptor agonist use was not associated with a higher risk of suicidality than DPP-4 inhibitors or SGLT-2 inhibitors after confounding adjustment. The crude associations attenuated to null after weighting, and the same pattern held for suicidal ideation, self-harm, and suicide analyzed separately.

## Key findings

  • In the GLP-1 receptor agonist vs DPP-4 inhibitor cohort, there were 36,082 GLP-1 receptor agonist users and 234,028 DPP-4 inhibitor users, with median follow-up of 1.3 and 1.7 years, respectively.
  • For the primary outcome, crude suicidality rates were 3.9 vs 1.8 per 1,000 person-years and the crude hazard ratio was 2.08 (95% CI 1.83 to 2.36); after weighting, the hazard ratio was 1.02 (0.85 to 1.23).
  • In the GLP-1 receptor agonist vs SGLT-2 inhibitor cohort, there were 32,336 GLP-1 receptor agonist users and 96,212 SGLT-2 inhibitor users, with median follow-up of 1.2 years in both groups.
  • For the primary outcome in that cohort, crude suicidality rates were 4.3 vs 2.7 per 1,000 person-years and the crude hazard ratio was 1.60 (95% CI 1.37 to 1.87); after weighting, the hazard ratio was 0.91 (0.73 to 1.12).
  • Secondary outcomes showed similar null findings after adjustment: vs DPP-4 inhibitors, weighted hazard ratios were 1.00 for suicidal ideation, 0.94 for self-harm, and 0.77 for suicide; vs SGLT-2 inhibitors, they were 0.84 for suicidal ideation, 1.03 for self-harm, and 0.14 for suicide, with wide confidence intervals for suicide.

## Methods

  • Active comparator, new user cohort study emulating two target trials: GLP-1 receptor agonists vs DPP-4 inhibitors and GLP-1 receptor agonists vs SGLT-2 inhibitors.
  • Data came from UK CPRD GOLD and Aurum, linked to Hospital Episode Statistics Admitted Patient Care and ONS Death Registration databases; patients were followed until outcome, discontinuation/switching, death, end of registration, or 29 March 2021.
  • The main analysis used propensity score fine stratification weighting and weighted Cox proportional hazards models to estimate hazard ratios for suicidality, with secondary analyses by individual outcome, subgroup, and sensitivity analyses.

## Limitations

  • The paper states that, as with all observational studies, residual confounding is possible; this is noted explicitly in the Discussion.
  • The paper states that CPRD does not include prescriptions written by specialists and that exposure misclassification is possible because prescriptions are recorded when written, not necessarily when filled.
  • The paper states that restricting self-harm to hospital admission events maximized specificity but could lead to outcome misclassification; it also notes that rare outcomes produced wide confidence intervals in some secondary analyses.
  • Evident from the text: the primary analysis excluded self-harm recorded only in primary care, though the authors report a sensitivity analysis expanding the outcome definition yielded nearly identical results.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmj-2024-080679

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Study flow diagram of patients in UK Clinical Practice Research Datalink starting glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase-4 (DPP-4) inhibitor between 1 January 2007 and 31 December 2020
Fig 1 Study flow diagram of patients in UK Clinical Practice Research Datalink starting glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase-4 (DPP-4) inhibitor between 1 January 2007 and 31 December 2020CC BY-NC · PubMed Central
Fig 2 Weighted cumulative incidence curves for composite of suicidal ideation, self-harm, or completed suicide among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus patients taking dipeptidyl peptidase-4 (DPP-4) inhibitor
Fig 2 Weighted cumulative incidence curves for composite of suicidal ideation, self-harm, or completed suicide among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus patients taking dipeptidyl peptidase-4 (DPP-4) inhibitorCC BY-NC · PubMed Central
Fig 3 Hazard ratios and 95% confidence intervals (CIs) from sensitivity analyses for composite outcome of suicidal ideation, self-harm, or completed suicide among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus patients taking dipeptidyl peptidase-4 (DPP-4) inhibitor. CPRD=Clinical Practice Research Datalink
Fig 3 Hazard ratios and 95% confidence intervals (CIs) from sensitivity analyses for composite outcome of suicidal ideation, self-harm, or completed suicide among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus patients taking dipeptidyl peptidase-4 (DPP-4) inhibitor. CPRD=Clinical Practice Research DatalinkCC BY-NC · PubMed Central
Fig 4 Study flow diagram of patients in UK Clinical Practice Research Datalink starting glucagon-like peptide-1 receptor agonist (GLP-1) or sodium-glucose cotransporter-2 (SGLT-2) inhibitor between 1 January 2013 and 31 December 2020
Fig 4 Study flow diagram of patients in UK Clinical Practice Research Datalink starting glucagon-like peptide-1 receptor agonist (GLP-1) or sodium-glucose cotransporter-2 (SGLT-2) inhibitor between 1 January 2013 and 31 December 2020CC BY-NC · PubMed Central
Fig 5 Weighted cumulative incidence curves for composite of suicidal ideation, self-harm, or completed suicide among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus patients taking sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Fig 5 Weighted cumulative incidence curves for composite of suicidal ideation, self-harm, or completed suicide among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus patients taking sodium-glucose cotransporter-2 (SGLT-2) inhibitorCC BY-NC · PubMed Central
Fig 6 Hazard ratios and 95% confidence intervals (CIs) from sensitivity analyses for composite outcome of suicidal ideation, self-harm, or completed suicide among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus patients taking sodium-glucose cotransporter-2 (SGLT-2) inhibitor. CPRD=Clinical Practice Research Datalink
Fig 6 Hazard ratios and 95% confidence intervals (CIs) from sensitivity analyses for composite outcome of suicidal ideation, self-harm, or completed suicide among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus patients taking sodium-glucose cotransporter-2 (SGLT-2) inhibitor. CPRD=Clinical Practice Research DatalinkCC BY-NC · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 3 Not checked · 45 Own results and interpretations

28 more claims

Create a free account to see all 58 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 13
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 40 references

Cited by

See all 49

Metadata

Authors
Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L.
Affiliations
Jewish General Hospital (CA)
Corresponding author
Azoulay, Laurent
Venue
BMJ
Publisher
BMJ
Published
2025-02-26
Volume
388
Pages
e080679
ISSN
1756-1833 (ISSN-L)
OpenAlex
W4407947558
Cited by
49
References
40
Citations by year
2026: 29 · 2025: 20
FWCI
33.17
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
GLP-1 receptor agonists, type 2 diabetes, suicidality, suicidal ideation, self-harm, suicide, DPP-4 inhibitors, SGLT2 inhibitors, antidepressant discontinuation, antidepressant prescribing, adverse drug reactions, antipsychotic prescribing
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Suicide, Cohort Studies, Self-Injurious Behavior, Dipeptidyl-Peptidase IV Inhibitors, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. https://app.cochat.ai/papers/10.1136/bmj-2024-080679
The paper
Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L. (2025). Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ. https://doi.org/10.1136/bmj-2024-080679

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.